127 related articles for article (PubMed ID: 38540686)
1. SPINK1 Overexpression Correlates with Hepatocellular Carcinoma Treatment Resistance Revealed by Single Cell RNA-Sequencing and Spatial Transcriptomics.
Yang C; Guo L; Du J; Zhang Q; Zhang L
Biomolecules; 2024 Feb; 14(3):. PubMed ID: 38540686
[TBL] [Abstract][Full Text] [Related]
2. Serine Protease Inhibitor Kazal Type 1, A Potential Biomarker for the Early Detection, Targeting, and Prediction of Response to Immune Checkpoint Blockade Therapies in Hepatocellular Carcinoma.
Jia J; Ga L; Liu Y; Yang Z; Wang Y; Guo X; Ma R; Liu R; Li T; Tang Z; Wang J
Front Immunol; 2022; 13():923031. PubMed ID: 35924241
[TBL] [Abstract][Full Text] [Related]
3. Serine peptidase inhibitor Kazal type 1 (SPINK1) as novel downstream effector of the cadherin-17/β-catenin axis in hepatocellular carcinoma.
Shek FH; Luo R; Lam BYH; Sung WK; Lam TW; Luk JM; Leung MS; Chan KT; Wang HK; Chan CM; Poon RT; Lee NP
Cell Oncol (Dordr); 2017 Oct; 40(5):443-456. PubMed ID: 28631187
[TBL] [Abstract][Full Text] [Related]
4. SPINK1-induced tumor plasticity provides a therapeutic window for chemotherapy in hepatocellular carcinoma.
Man KF; Zhou L; Yu H; Lam KH; Cheng W; Yu J; Lee TK; Yun JP; Guan XY; Liu M; Ma S
Nat Commun; 2023 Nov; 14(1):7863. PubMed ID: 38030644
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of tumor-associated trypsin inhibitor (SPINK1/TATI) in hepatitis C-associated hepatocellular carcinoma: potential implications for viral hepatocarcinogenesis.
Hass HG; Jobst J; Vogel U; Scheurlen M; Nehls O
Oncol Res Treat; 2014; 37(12):732-8. PubMed ID: 25531719
[TBL] [Abstract][Full Text] [Related]
6. High SPINK1 Expression Predicts Poor Prognosis and Promotes Cell Proliferation and Metastasis of Hepatocellular Carcinoma.
Huang K; Xie W; Wang S; Li Q; Wei X; Chen B; Hua Y; Li S; Peng B; Shen S
J Invest Surg; 2021 Sep; 34(9):1011-1020. PubMed ID: 32066292
[TBL] [Abstract][Full Text] [Related]
7. Serine protease inhibitor Kazal type 1 (SPINK1) downregulates E-cadherin and induces EMT of hepatoma cells to promote hepatocellular carcinoma metastasis via the MEK/ERK signaling pathway.
Ying HY; Gong CJ; Feng Y; Jing DD; Lu LG
J Dig Dis; 2017 Jun; 18(6):349-358. PubMed ID: 28544403
[TBL] [Abstract][Full Text] [Related]
8. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
[TBL] [Abstract][Full Text] [Related]
9. The Diagnostic Role of SPINK1 in Differentiating Hepatocellular Carcinoma From Nonmalignant Lesions.
Holah NS; El-Azab DS; Aiad HAE; Sweed DMM
Appl Immunohistochem Mol Morphol; 2017; 25(10):703-711. PubMed ID: 27028242
[TBL] [Abstract][Full Text] [Related]
10. Performance of SPINK1 and SPINK1-based diagnostic model in detection of hepatocellular carcinoma.
Wang F; Liu H; Bai Y; Li H; Wang Z; Xu X
J Clin Lab Anal; 2021 Nov; 35(11):e24025. PubMed ID: 34569662
[TBL] [Abstract][Full Text] [Related]
11. Increased effects of 2,5-dimethylcelecoxib on sensitivity of hepatocellular carcinoma cells to sorafenib via CYP3A5 expression and activation of AMPK.
Chen Y; Pan B; Qiu J; Chen Z; Wang X; Tang N
Toxicol In Vitro; 2021 Oct; 76():105226. PubMed ID: 34293431
[TBL] [Abstract][Full Text] [Related]
12. Increased Serum Levels of Trypsin Inhibitor Kazal1 in Patients with HBV-Related Hepatocellular Carcinoma Predict a Poor Prognosis.
Yan RR; Zhu T; Wang Q; Yang K; Li J; Guan SH
Clin Lab; 2021 Jan; 67(1):. PubMed ID: 33491427
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis B Virus X Protein-Induced Serine Protease Inhibitor Kazal Type 1 Is Associated with the Progression of HBV-Related Diseases.
Zhu C; Han H; Li J; Xu L; Liu F; Wu K; Liu X
Biomed Res Int; 2019; 2019():9321494. PubMed ID: 31240230
[TBL] [Abstract][Full Text] [Related]
14. MAPK inhibitors induce serine peptidase inhibitor Kazal type 1 (SPINK1) secretion in BRAF V600E-mutant colorectal adenocarcinoma.
Räsänen K; Dang KX; Mustonen H; Ho TH; Lintula S; Koistinen H; Stenman UH; Haglund C; Stenman J
Mol Oncol; 2018 Feb; 12(2):224-238. PubMed ID: 29193645
[TBL] [Abstract][Full Text] [Related]
15. ID1 promotes hepatocellular carcinoma proliferation and confers chemoresistance to oxaliplatin by activating pentose phosphate pathway.
Yin X; Tang B; Li JH; Wang Y; Zhang L; Xie XY; Zhang BH; Qiu SJ; Wu WZ; Ren ZG
J Exp Clin Cancer Res; 2017 Nov; 36(1):166. PubMed ID: 29169374
[TBL] [Abstract][Full Text] [Related]
16. Oxaliplatin resistance is enhanced by saracatinib via upregulation Wnt-ABCG1 signaling in hepatocellular carcinoma.
Liao X; Song G; Xu Z; Bu Y; Chang F; Jia F; Xiao X; Ren X; Zhang M; Jia Q
BMC Cancer; 2020 Jan; 20(1):31. PubMed ID: 31931755
[TBL] [Abstract][Full Text] [Related]
17. Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Is a Novel Prognostic Marker and Contributes to Sorafenib Resistance in Hepatocellular Carcinoma.
Dietrich P; Gaza A; Wormser L; Fritz V; Hellerbrand C; Bosserhoff AK
Neoplasia; 2019 Mar; 21(3):257-268. PubMed ID: 30685691
[TBL] [Abstract][Full Text] [Related]
18. TAK1 Is a Novel Target in Hepatocellular Carcinoma and Contributes to Sorafenib Resistance.
Xia S; Ji L; Tao L; Pan Y; Lin Z; Wan Z; Pan H; Zhao J; Cai L; Xu J; Cai X
Cell Mol Gastroenterol Hepatol; 2021; 12(3):1121-1143. PubMed ID: 33962073
[TBL] [Abstract][Full Text] [Related]
19. LncRNA LIMT (LINC01089) contributes to sorafenib chemoresistance via regulation of miR-665 and epithelial to mesenchymal transition in hepatocellular carcinoma cells.
Sun J; Zheng X; Wang B; Cai Y; Zheng L; Hu L; Lu X; Xie S; Zhang X; Liu H; Ye L
Acta Biochim Biophys Sin (Shanghai); 2022 Jan; 54(2):261-270. PubMed ID: 35130616
[TBL] [Abstract][Full Text] [Related]
20. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]